The use of metabolites and analogues of vitamin D in prospective renal transplant recipients
Cundy, T.; Kanis, J.A.; Fraher, L.; Clemens, T.L.; O'Riordan, J.L.
Clinical Nephrology 15(5): 240-245
1981
ISSN/ISBN: 0301-0430 PMID: 7018772 Document Number: 172604
Hypercalcemia developed acutely at the time of transplantation in 2 dialysis-treated patients previously taking 25-hydroxy vitamin D3 for renal bone disease. Significant hypercalcemia was not observed in 7 other transplant recipients who had previously taken 1.alpha.-hydroxylated derivatives of vitamin D3 nor in 9 untreated patients. In view of the dangers of severe hypercalcemia to graft function, the use of 1.alpha.-hydroxylated derivatives of vitamin D3 is preferable to pharmacological doses of long-acting forms of vitamin D in patients with renal failure likely to receive kidney transplants.